Kedrion Warns of Plasma Supply Disruptions to Iran Amid Strait of Hormuz Tensions

Key Facts

Italian biopharmaceutical giant Kedrion has issued a formal warning regarding potential difficulties in delivering vital plasma-based medicines to patients in Iran. The company attributed these looming disruptions to persistent shipping instabilities and logistical challenges within the Strait of Hormuz. As a critical supplier of life-saving treatments, Kedrion noted that regional maritime tensions are increasingly threatening the integrity of medical supply chains. This development follows broader reports of logistics firms struggling with heightened insurance costs and operational risks in Middle Eastern waterways. The situation underscores the growing impact of geopolitical friction on the delivery of essential humanitarian and medical goods. Analysts suggest that such disruptions could lead to critical shortages in the Iranian healthcare sector if maritime security does not stabilize.